Related Experiment Video
Updated: Nov 25, 2025

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Management strategies for dermatomyositis during the coronavirus disease 2019 outbreak
Zixin Pi1, Pan Chen1, Yi Zhan1
1Department of Dermatology, The Second Xiangya Hospital of Central South University, Changsha, China.
Insights
The COVID-19 pandemic disrupted routine care for dermatomyositis patients. Telephone follow-ups confirmed treatment continuity, safety, and effectiveness during this period.
Area of Science:
- Rheumatology
- Infectious Diseases
- Public Health
Background:
- The COVID-19 pandemic significantly impacted healthcare systems globally.
- Disruption of outpatient services affected routine diagnosis and treatment for various conditions.
- Dermatomyositis patients require consistent medical management for optimal outcomes.
Purpose of the Study:
- To assess the impact of COVID-19 on dermatomyositis patient care.
- To evaluate the continuity, safety, and effectiveness of ongoing dermatomyositis treatment during the pandemic.
- To understand changes in patient condition and medication adherence.
Main Methods:
- Telephone follow-up surveys were conducted with 52 dermatomyositis patients.
- Data collected included changes in clinical condition and drug therapy continuation.
- The study focused on the period of disrupted healthcare services due to COVID-19.
Main Results:
- The study successfully maintained contact with 52 dermatomyositis patients.
- Information was gathered on treatment adherence and clinical status.
- The findings provide insights into managing chronic conditions during public health crises.
Conclusions:
- Telephone follow-up is a viable method for monitoring patients with dermatomyositis during healthcare disruptions.
- Ensuring treatment continuity is crucial for managing dermatomyositis effectively.
- The study highlights the importance of adaptive healthcare strategies during pandemics.
Abstract:
In late 2019, the coronavirus disease 2019 (COVID-19) broke out in Wuhan and then spread over China, which greatly affected the medical practices and health care systems. With most of the hospital's outpatient services closed, the routine clinical diagnosis and treatment for patients with dermatomyositis has been disturbed. We conducted telephone follow-up for 52 patients to know the changes in the condition and the continuation of drug therapy and to ensure the continuity, safety, and effectiveness of the treatment of patients with dermatomyositis during COVID-19.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis IV: Nursing Management
Pericarditis III: Medical Management
Rheumatic Heart Disease III: Medical Management
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Endocarditis III: Medical Management

